Pfizer COVID-19 vaccine promising
Pfizer and its collaborator, BioNTech have announced positive efficacy results from their Phase 3, late-stage study of their potential COVID-19 vaccine. The announcement, issued on Monday November 12, 2020 vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis.
“The results demonstrate that our mRNA-based vaccine can help prevent COVID-19 in the majority of people who receive it. This means we are one step closer to potentially providing people around the world with a much-needed breakthrough to help bring an end to this global pandemic,” said Alfred Bourla,Chairman and Chief Executive Officer, Pfizer. “This is a first but critical step in our work to deliver a safe and effective vaccine,” said Dr Bourla.
On 1 April 2020, EuroTimes reported that Pfizer was teaming up with BioNTech to rapidly develop the Mainz, Germany-based firm’s BNT162, a messenger RNA-based potential vaccine for COVID-19.
The compound was expected to enter clinical testing by the end of April 2020, according to the two companies. If successful, it would prevent contraction of COVID-19 in patients not previously exposed to the SARS-Cov-2 coronavirus that causes the disease.
BNT162 builds on BioNTech’s 2018 research and development collaboration with Pfizer to develop mRNA-based influenza vaccines. The method does not use neutralised virus to prompt host immune systems to develop antibodies to the live disease virus, as with traditional vaccines. Instead, mRNA from the virus is used to produce proteins in the body that are similar enough to the target virus to stimulate production of antibodies that will attack the actual virus should it appear.